Myeloma News and Research

RSS

Two novel drugs kill breast cancer tumor cells

Two new drugs, when combined, killed up to 75 percent of breast cancer tumor cells in mice and suppressed the regrowth of tumors, according to researchers at the Virginia Commonwealth University Massey Cancer Center.

26 Nov 2005

Compound from Salinispora (marine bacteria) kills blood cancer cells

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

21 Nov 2005

New treatments suggest that cancer is on the run!

People suffering from cancer will be encouraged by a cluster of recent reports on successful new treatments for several different forms of cancer.

24 Oct 2005

Researchers learn to rapidly rebuild immunity in immune-suppressed cancer patients

Patients with multiple myeloma suffer from a malignant proliferation of plasma cells in their bone marrow. The standard treatment for this form of cancer is high-dose chemotherapy and transplantation of one's own blood-producing adult stem cells; however, this aggressive treatment wipes out the mature immune-system cells of patients – leaving them vulnerable to infection.

20 Oct 2005

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection, according to immunologists at Duke University Medical Center.

11 Oct 2005

Scintigraphy scan may help clinicians properly diagnose and then treat two forms of cardiac amyloidosis

"Clinically, this finding helps differential diagnosis and reduces the risk of misdiagnosis between two conditions with very different therapeutic options," said Claudio Rapezzi, M.D. from the University of Bologna and S. Orsola-Malpighi Hospital in Bologna, Italy.

21 Sep 2005

Drug AMD-3100 may help cancer patients who need stem cell transplants

A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.

19 Sep 2005

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

1 Sep 2005

Relative of the celebrated COX-2 inhibitor celecoxib is tough tumor fighter

A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.

29 Aug 2005

Loyola researchers hope that zoledronic acid will be effective and safe for patients with inflammatory bowel diseases (IBD)

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

26 Jul 2005

Breast cancer drug Herceptin soon to be widely available on NHS

The British health secretary Patricia Hewitt has ordered a fast-track assessment of Herceptin, a drug which has shown great promise in treating the early stages of breast cancer.

23 Jul 2005

$New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer$

New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer

When breast cancer spreads to bones, relatively new protective drugs called bisphosphonates can reduce skeletal damage, says a new systematic review of previous studies. While the new treatment approach does not improve survival rates, it can minimize disabling fractures, spinal cord compression and pain.

19 Jul 2005

Curcumin has potent anticancer powers

Curcumin, a spice commonly used in curries and other south Asian cooking, blocks a key biological pathway needed for development of melanoma and other cancers, say researchers from the University of Texas M. D. Anderson Cancer Center.

12 Jul 2005

Thalidomide may be a potent anti-cancer treatment

When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment.

20 Jun 2005

Novel strategy proves highly effective in killing drug-resistant multiple myeloma cells

A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory and could open a new form of attack on the deadly blood cancer, they report.

2 Jun 2005

No link found between hair dyes and cancers

The growing worldwide concern about a possible link between hair dyes and some forms of cancer, which was further fuelled by one recent study showing an apparent positive relationship, prompted a European Commission safety panel to call for an urgent review.

24 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

A new vaccine designed at The Rockefeller University boosted a type of fast-responding immune system cell called the natural killer T (NKT) cell in patients with advanced cancer. The study surprised researchers by revealing the ability of these NKT cells to spur other, slower-responding immune cells to go to work.

4 May 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

Revlimid results look promising for multiple myeloma patients

The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.

8 Mar 2005